US Court of Appeals Upholds Gilenya Compound Patent, Dealing A Blow To Ezra Ventures

Upholding the validity of Novartis’ Gilenya compound patent, a US Court of Appeals ensures that US-based Ezra’s generic fingolimod hydrochloride product will stay off the market until at least 2019. Generics players challenging the blockbuster multiple-sclerosis brand's patents have had mixed fortunes thus far.